Prostate Cancer
Advertisement
An analysis of the phase 3 ARASENS study revealed new information on PSA responses and their association with outcomes.
A CR was observed in the first patient with mCRPC to receive 2 cycles of 67Cu-SAR-bisPSMA at a dosage of 8GBq.
Dr. Vandekerkhove explains her research on genomic testing in prostate cancer.
The benefits of PSA screening alone are offset by excess negative biopsies and the over-detection of low-grade cancers.
The study sought to determine the outcomes and prevalence related to somatic or germline HRR alterations.
Researchers performed a post hoc analysis on patient data from the randomized, phase 3 LATITUDE trial.
Dr. Spratt ponders the evolving integration of RT with systemic treatments, challenges in counseling patients, and more.
Dr. Iagaru discusses the safety findings and clinical implications of his research.
Dr. Ulaner highlights 2 new clinical trials for prostate cancer staging and treatment at Hoag: MIRROR and 177Lu-PNT2002.
The data were sourced from a deidentified US-based metastatic prostate cancer clinicogenomic database.
Dr. Gomella tells his journey to becoming a urologist, the importance of multidisciplinary care, and challenges in the field.
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Prostate-specific antigen density was the only clinical variable significantly associated with csPCa other than PI-RADS 5.
Dr. Canfield shares real-world active surveillance among men with localized PC tested with the genomic prostate score assay.
The 17-gene GPS assay can help physicians with clinical management plans for patients with localized PC.
cN1 patients with PCa who undergo initial treatment with RT have worse PCSM outcomes than those treated with RP.
Dr. Spratt reviews the safety and efficacy of relugolix plus RT in patients with localized or advanced prostate cancer.
Dr. Gupta traces the trajectory of her career and describes her commitment to advancing the field through innovative trials.
Dr. James Sylora shares his career, patient care, and vision for surgical and therapy advancements in community urology.
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.